Cargando…

Plasma Levels of Oxidative Stress Markers, before and after BoNT/A Treatment, in Chronic Migraine

The pathophysiological mechanisms of migraine transformation are debated. Modifications of plasma oxidative stress biomarkers have been described in chronic migraine. OnabotulintoxinA (BoNT/A) treatment, approved for chronic migraine prophylaxis, possibly reduces pain neurotransmitters release and o...

Descripción completa

Detalles Bibliográficos
Autores principales: Dini, Elisa, Mazzucchi, Sonia, De Luca, Ciro, Cafalli, Martina, Chico, Lucia, Lo Gerfo, Annalisa, Siciliano, Gabriele, Bonuccelli, Ubaldo, Baldacci, Filippo, Gori, Sara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6832499/
https://www.ncbi.nlm.nih.gov/pubmed/31635021
http://dx.doi.org/10.3390/toxins11100608
_version_ 1783466187152162816
author Dini, Elisa
Mazzucchi, Sonia
De Luca, Ciro
Cafalli, Martina
Chico, Lucia
Lo Gerfo, Annalisa
Siciliano, Gabriele
Bonuccelli, Ubaldo
Baldacci, Filippo
Gori, Sara
author_facet Dini, Elisa
Mazzucchi, Sonia
De Luca, Ciro
Cafalli, Martina
Chico, Lucia
Lo Gerfo, Annalisa
Siciliano, Gabriele
Bonuccelli, Ubaldo
Baldacci, Filippo
Gori, Sara
author_sort Dini, Elisa
collection PubMed
description The pathophysiological mechanisms of migraine transformation are debated. Modifications of plasma oxidative stress biomarkers have been described in chronic migraine. OnabotulintoxinA (BoNT/A) treatment, approved for chronic migraine prophylaxis, possibly reduces pain neurotransmitters release and oxidative stress products. Aims of our study were to investigate differences in the levels of selected plasmatic oxidative stress biomarkers (Advanced Oxidation Protein Products (AOPP), Ferric Reducing Antioxidant Power (FRAP), Thiolic Groups (SH)) comparing chronic migraineurs (CM) and healthy controls (HC). We also explored possible clinical and biochemical modifications in the CM group after six months of treatment with BoNT/A. At the baseline, we found higher values of AOPP (p < 0.001), and lower values of SH (p < 0.001) and FRAP (p = 0.005) in the CM group. At the six-month follow-up we found a reduction of AOPP (p < 0.001) and an increase of FRAP (p < 0.001) and SH (p = 0.023) within the CM group. BoNT/A treatment improved migraine symptoms in the CM group. We confirmed previous reports of imbalanced antioxidant mechanisms in chronic migraine showing lower antioxidant capacities in patients than controls. BoNT/A improved the levels of plasma oxidative stress biomarkers and confirmed its role as an effective prophylactic treatment for CM. Other studies should investigate the potential antioxidant properties of BoNT/A treatment.
format Online
Article
Text
id pubmed-6832499
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-68324992019-11-25 Plasma Levels of Oxidative Stress Markers, before and after BoNT/A Treatment, in Chronic Migraine Dini, Elisa Mazzucchi, Sonia De Luca, Ciro Cafalli, Martina Chico, Lucia Lo Gerfo, Annalisa Siciliano, Gabriele Bonuccelli, Ubaldo Baldacci, Filippo Gori, Sara Toxins (Basel) Article The pathophysiological mechanisms of migraine transformation are debated. Modifications of plasma oxidative stress biomarkers have been described in chronic migraine. OnabotulintoxinA (BoNT/A) treatment, approved for chronic migraine prophylaxis, possibly reduces pain neurotransmitters release and oxidative stress products. Aims of our study were to investigate differences in the levels of selected plasmatic oxidative stress biomarkers (Advanced Oxidation Protein Products (AOPP), Ferric Reducing Antioxidant Power (FRAP), Thiolic Groups (SH)) comparing chronic migraineurs (CM) and healthy controls (HC). We also explored possible clinical and biochemical modifications in the CM group after six months of treatment with BoNT/A. At the baseline, we found higher values of AOPP (p < 0.001), and lower values of SH (p < 0.001) and FRAP (p = 0.005) in the CM group. At the six-month follow-up we found a reduction of AOPP (p < 0.001) and an increase of FRAP (p < 0.001) and SH (p = 0.023) within the CM group. BoNT/A treatment improved migraine symptoms in the CM group. We confirmed previous reports of imbalanced antioxidant mechanisms in chronic migraine showing lower antioxidant capacities in patients than controls. BoNT/A improved the levels of plasma oxidative stress biomarkers and confirmed its role as an effective prophylactic treatment for CM. Other studies should investigate the potential antioxidant properties of BoNT/A treatment. MDPI 2019-10-19 /pmc/articles/PMC6832499/ /pubmed/31635021 http://dx.doi.org/10.3390/toxins11100608 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Dini, Elisa
Mazzucchi, Sonia
De Luca, Ciro
Cafalli, Martina
Chico, Lucia
Lo Gerfo, Annalisa
Siciliano, Gabriele
Bonuccelli, Ubaldo
Baldacci, Filippo
Gori, Sara
Plasma Levels of Oxidative Stress Markers, before and after BoNT/A Treatment, in Chronic Migraine
title Plasma Levels of Oxidative Stress Markers, before and after BoNT/A Treatment, in Chronic Migraine
title_full Plasma Levels of Oxidative Stress Markers, before and after BoNT/A Treatment, in Chronic Migraine
title_fullStr Plasma Levels of Oxidative Stress Markers, before and after BoNT/A Treatment, in Chronic Migraine
title_full_unstemmed Plasma Levels of Oxidative Stress Markers, before and after BoNT/A Treatment, in Chronic Migraine
title_short Plasma Levels of Oxidative Stress Markers, before and after BoNT/A Treatment, in Chronic Migraine
title_sort plasma levels of oxidative stress markers, before and after bont/a treatment, in chronic migraine
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6832499/
https://www.ncbi.nlm.nih.gov/pubmed/31635021
http://dx.doi.org/10.3390/toxins11100608
work_keys_str_mv AT dinielisa plasmalevelsofoxidativestressmarkersbeforeandafterbontatreatmentinchronicmigraine
AT mazzucchisonia plasmalevelsofoxidativestressmarkersbeforeandafterbontatreatmentinchronicmigraine
AT delucaciro plasmalevelsofoxidativestressmarkersbeforeandafterbontatreatmentinchronicmigraine
AT cafallimartina plasmalevelsofoxidativestressmarkersbeforeandafterbontatreatmentinchronicmigraine
AT chicolucia plasmalevelsofoxidativestressmarkersbeforeandafterbontatreatmentinchronicmigraine
AT logerfoannalisa plasmalevelsofoxidativestressmarkersbeforeandafterbontatreatmentinchronicmigraine
AT sicilianogabriele plasmalevelsofoxidativestressmarkersbeforeandafterbontatreatmentinchronicmigraine
AT bonuccelliubaldo plasmalevelsofoxidativestressmarkersbeforeandafterbontatreatmentinchronicmigraine
AT baldaccifilippo plasmalevelsofoxidativestressmarkersbeforeandafterbontatreatmentinchronicmigraine
AT gorisara plasmalevelsofoxidativestressmarkersbeforeandafterbontatreatmentinchronicmigraine